Skip to content

Sublingual misoprostol to reduce blood loss at cesarean delivery

Sublingual misoprostol to reduce blood loss at cesarean delivery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016030126857N1
Enrollment
90
Registered
2017-01-18
Start date
2016-11-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum hemorrhage. Haemorrhage after delivery of fetus or infant

Interventions

Intervention 1: intervention group: 30 unite intravenous oxytocin in 1000 cc ringer infusion [10ml/m] in 30 minutes and then 2 ml/min for next 6 hours plus 400 microgram sublingual misoprostol after c
Treatment - Drugs
intervention group: 30 unite intravenous oxytocin in 1000 cc ringer infusion [10ml/m] in 30 minutes and then 2 ml/min for next 6 hours plus 400 microgram sublingual misoprostol after cord clamping
control group: intervention group: 30 unite intravenous oxytocin in 1000 cc ringer infusion [10ml/m] in 30 minutes and then 2 ml/min for next 6 hours

Sponsors

Vice President of Research of mashhad university of medical science
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: inclusion criteria: the term pregnant women with risk factor for post partum hemorrhage such as uterine overdistention (multifetal gestatation.macrosomia), arrest disorder, prolonged induction and prolonged preterm rupture of membrane exclusion criteria: Lack of consent, coagulation disorders , Anemia, Intraabdominal adhesion, Intraoperative bladder and intestines and other viscera damage, Abnormal adhesion of placenta, extended Uterine incision during cesarean delivery and known hypersensitivity to misoprostol.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Mean estimate blood loss. Timepoint: During surgery. Method of measurement: Milliliter.

Secondary

MeasureTime frame
Adverse effect. Timepoint: In the first day after surgery. Method of measurement: presence or absence.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Roya Jalali

Mashhad University of Medical Sciences

jalalir921@mums.ac.ir+98 51 3868 6050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026